Keyphrases
Risk Stratification
100%
Chemoresistant
100%
Pembrolizumab
100%
Urothelial Cancer
100%
Intermediate-risk Group
100%
High-risk Population
100%
Confidence Interval
66%
Overall Survival
66%
Hazard Ratio
66%
Urothelial Carcinoma
66%
Median Overall Survival
66%
Overall Survival Time
66%
Validation Cohort
66%
Multivariate Model
66%
Low-intermediate Risk
66%
Independent Prognostic Factor
33%
Patient Characteristics
33%
Objective Response Rate
33%
Immune Checkpoint Inhibitors
33%
Multicenter Retrospective Study
33%
First-line Chemotherapy
33%
Patient Outcomes
33%
External Validation
33%
Differential Outcomes
33%
Performance Status
33%
Risk Score
33%
Well-balancing
33%
Neutrophil-to-lymphocyte Ratio
33%
Group Discovery
33%
Prognostic Model
33%
Patient Counseling
33%
Oncological Outcomes
33%
Score-based
33%
Hemoglobin Level
33%
Low-risk Group
33%
Clinical Trial Design
33%
Metastasis Sites
33%
Medicine and Dentistry
Risk Stratification
100%
Overall Survival
100%
Pembrolizumab
100%
Urothelial Cancer
100%
High Risk Population
75%
Intermediate Risk Population
75%
Hazard Ratio
50%
Transitional Cell Carcinoma
50%
Survival Time
50%
Patient Characteristics
25%
Metastatic Carcinoma
25%
Retrospective Study
25%
Prognostic Factor
25%
First-Line Chemotherapy
25%
Clinical Trial Design
25%
Patient Counseling
25%
Neutrophil
25%
Low Risk Population
25%
Immune Checkpoint Inhibitor
25%
Lymphocyte
25%
Biochemistry, Genetics and Molecular Biology
Overall Survival
100%
Pembrolizumab
100%
High Risk Population
75%
Intermediate Risk Population
75%
Survival Time
50%
Clinical Trial Design
25%
Neutrophil-To-Lymphocyte Ratio
25%
Low Risk Population
25%
Hemoglobin Blood Level
25%
Immune Checkpoints
25%
Retrospective Study
25%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Overall Survival
100%
Pembrolizumab
100%
Transitional Cell Carcinoma
50%
Survival Time
50%
First-Line Chemotherapy
25%
Retrospective Study
25%
Immune Checkpoint Inhibitor
25%
Clinical Trial Design
25%